Optimization of AO drugs 45, 51 & 53

AO药物的优化 45, 51

• 批准号: 8102467
• 负责人: Qi L Lu
• 金额: $ 24.17万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8102467
• 关键词: Affect; Antisense Oligonucleotides; Axon; Biochemical; Biological Markers; Biopsy; Birth; Cell Culture Techniques; Cells; Clinical Trials; Development; Disease; Drug Approval; Drug Delivery Systems; Duchenne muscular dystrophy; Dystrophin; Exons; Fibroblasts; Funding; Future; Genes; Genetic Code; Grant; Human; In Vitro; Introns; Life; Medicine; Methods; Modality; Mus; Muscular Dystrophies; Mutation; Myoblasts; Myotonic Dystrophy; Patients; Pharmaceutical Preparations; Process; Reporter; Research; Safety; Screening procedure; Skin; Staging; Subgroup; System; Testing; Therapeutic; Time; Translational Research; United States National Institutes of Health; base; cost; drug development; drug testing; in vivo; influenza virus vaccine; male; mouse model; preclinical study; programs; restoration; therapeutic target

Systemic delivery of antisense oligonucleotides to drive exon skipping, and restoration of dystrophin expression, has the most promise as a therapeutic for the majority of Duchenne muscular dystrophy (DMD) patients. Similar approaches are also in early stage development for SMA and myotonic dystrophy. A challenge with the exon skipping approach for DMD is the requirement for many distinct drugs targeting different exons. Indeed, exon skipping is being considered by the FDA as an early example of personalized medicine, where drug development is optimized for the specific patient genetic code. This complicates the drug development process, greatly increasing potential cost and time required for diminishing numbers of DMD patients. An alternative approach, used for flu vaccines, is approval 'as a class'. The initial three AO drugs applicable to the greatest number of patients are exons 45, 51, and 53. Once safety and efficacy is proven with these three exon-specific drugs, approval of exon skipping as a class may facilitate drug approvals for less common exons. In this project, we propose a systematic opfimization of AO drugs for exons 45, 51, and 53. Multiple in vitro and in vivo experimental systems will be utilized to validate potency of each drug. Part of the development process for axon 45 is currently funded by a NIH UOl to the PI of this project; this funded program will be extended to patient cell studies from Project 3 and Core C. For exons 51, and 53, the entire drug development process will be funded by the proposed research program. The last aim conducts a 6 month functional efficacy study of the truncated dystrophins in dystrophin-deficient mice lacking exon 52, and will test drugs optimized for both exons 51 and 53.

全身递送反义寡核苷酸以驱动外显子跳跃并恢复肌营养不良蛋白表达，最有希望成为大多数杜氏肌营养不良症 (DMD) 患者的治疗方法。针对 SMA 和强直性肌营养不良的类似方法也处于早期开发阶段。 DMD 外显子跳跃方法的一个挑战是需要许多针对不同外显子的不同药物。事实上，FDA 正在将外显子跳跃视为个性化医疗的早期示例，其中药物开发针对特定患者的遗传密码进行了优化。这使得药物开发过程变得复杂，大大增加了潜在的成本和减少 DMD 患者所需的时间。用于流感疫苗的另一种方法是“按类别”批准。适用于最多患者的最初三种 AO 药物是外显子 45、51 和 53。一旦证明这三种外显子特异性药物的安全性和有效性，批准外显子跳跃作为一类药物可能会促进不太常见外显子的药物批准。在这个项目中，我们提出对外显子 45、51 和 53 的 AO 药物进行系统优化。将利用多个体外和体内实验系统来验证每种药物的效力。轴突 45 的部分开发过程目前由 NIH UOl 资助该项目的 PI；该资助计划将扩展到项目 3 和核心 C 的患者细胞研究。对于外显子 51 和 53，整个药物开发过程将由拟议的研究计划资助。最后一个目标是对缺乏外显子 52 的肌营养不良蛋白缺陷小鼠中的截短肌营养不良蛋白进行为期 6 个月的功能功效研究，并将测试针对外显子 51 和 53 优化的药物。